Drug Industry Daily

View the entire issue.

As Sen. Max Baucus (D-Mont.) prepares to release details of his Senate Finance Committee’s draft healthcare legislation this week, he has found an ally in PhRMA.

Johnson & Johnson (J&J) is investing as much as $1.5 billion in Elan’s Alzheimer’s disease research.

The FDA Globalization Act, which has languished in committee since its January introduction, must be rewritten and introduced as a new bill because its food safety provisions were removed.

The FDA has approved Sanofi-Aventis’ atrial fibrillation (AF) treatment Multaq three years after issuing a not-approvable letter for the drug.

Teva Pharmaceuticals USA and Par Pharmaceutical are facing separate patent infringement lawsuits in a Delaware court — Teva over proposed generic versions of the erectile dysfunction drug Levitra and Par over the glaucoma treatments Travatan and Travatan Z.

Abbott Laboratories and Pfizer say the FDA’s secure supply-chain pilot program must significantly reduce import clearance times while reviewing documents for imported drugs and active pharmaceutical ingredients (APIs). 

The FDA has granted tentative approval for multiple strengths of Dr. Reddy’s Laboratories’ generic version of Zyprexa, Eli Lilly’s schizophrenia treatment.

Eisai plans to submit an NDA for a sustained-release (SR) formulation of its Alzheimer’s disease treatment Aricept in August or September.